iCAD, Inc. (NASDAQ:ICAD – Get Free Report) saw a large decrease in short interest during the month of July. As of July 31st, there was short interest totalling 187,800 shares, a decrease of 5.9% from the July 15th total of 199,500 shares. Currently, 0.8% of the company’s stock are short sold. Based on an average daily volume of 137,600 shares, the short-interest ratio is presently 1.4 days.
Institutional Trading of iCAD
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ICAD. Perritt Capital Management Inc raised its stake in iCAD by 14.2% during the 2nd quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock worth $208,000 after acquiring an additional 19,917 shares in the last quarter. Virtu Financial LLC lifted its holdings in shares of iCAD by 55.6% in the 1st quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock valued at $34,000 after purchasing an additional 7,604 shares during the last quarter. Perritt Capital Management Inc. grew its stake in iCAD by 7.5% during the 1st quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company’s stock worth $225,000 after buying an additional 9,717 shares during the last quarter. First Eagle Investment Management LLC increased its position in iCAD by 3.2% during the first quarter. First Eagle Investment Management LLC now owns 701,525 shares of the technology company’s stock worth $1,129,000 after buying an additional 22,000 shares during the period. Finally, AMH Equity Ltd purchased a new stake in iCAD in the first quarter valued at approximately $207,000. Institutional investors and hedge funds own 24.61% of the company’s stock.
Wall Street Analysts Forecast Growth
Separately, StockNews.com cut shares of iCAD from a “hold” rating to a “sell” rating in a research report on Wednesday, August 14th.
iCAD Stock Performance
NASDAQ:ICAD opened at $1.68 on Monday. iCAD has a 1 year low of $1.18 and a 1 year high of $2.65. The stock has a market cap of $44.59 million, a P/E ratio of -14.00 and a beta of 1.50. The stock has a 50-day simple moving average of $1.34 and a 200-day simple moving average of $1.50.
About iCAD
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Featured Articles
- Five stocks we like better than iCAD
- What is the Dow Jones Industrial Average (DJIA)?
- This Small Cap Wealth Management Stock Could Provide Big Returns
- What Are Trending Stocks? Trending Stocks Explained
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What Are Dividend Contenders? Investing in Dividend Contenders
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.